Healthequity, Inc.: Form 10-Q for the period ended Jul 31, 2025
Filed with the SEC on Sep 2, 2025 and accepted by EDGAR at Sep 2, 2025, 20:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-05-01 to 2025-07-31 | $325.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-02-01 to 2025-07-31 | $656.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-05-01 to 2025-07-31 | $93.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-02-01 to 2025-07-31 | $199.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-05-01 to 2025-07-31 | $232.6m | us-gaap:GrossProfit |
| Gross profit | 6 months2025-02-01 to 2025-07-31 | $456.9m | us-gaap:GrossProfit |
| Research and development | 3 months2025-05-01 to 2025-07-31 | $64.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-02-01 to 2025-07-31 | $126.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-05-01 to 2025-07-31 | $89.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-02-01 to 2025-07-31 | $172.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-05-01 to 2025-07-31 | $15.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-02-01 to 2025-07-31 | $29.8m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-05-01 to 2025-07-31 | $18.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-02-01 to 2025-07-31 | $35.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-05-01 to 2025-07-31 | $59.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-02-01 to 2025-07-31 | $113.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-05-01 to 2025-07-31 | $0.68 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-02-01 to 2025-07-31 | $1.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-05-01 to 2025-07-31 | $0.69 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-02-01 to 2025-07-31 | $1.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-05-01 to 2025-07-31 | 87,746,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-02-01 to 2025-07-31 | 88,153,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-02-01 to 2025-07-31 | $200.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-02-01 to 2025-07-31 | $859.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2025-02-01 to 2025-07-31 | $125.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-07-31 | $304.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-07-31 | $492.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-07-31 | $3.42bn | us-gaap:Assets |
| Current liabilities | At period end2025-07-31 | $116.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-07-31 | $1.27bn | us-gaap:Liabilities |
| Long-term debt | At period end2025-07-31 | $1.01bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-07-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-07-31 | $2.15bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001428336-25-000029. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.